Patents by Inventor Lee A. Mizzen
Lee A. Mizzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100010082Abstract: The present disclosure relates to ophthalmic solutions and methods of using the solutions to treat ocular disordersType: ApplicationFiled: July 9, 2009Publication date: January 14, 2010Applicant: Aspreva International Ltd.Inventors: Eddie CHONG, Clive BURGE, Lee MIZZEN
-
Publication number: 20080050399Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein —HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.Type: ApplicationFiled: July 26, 2007Publication date: February 28, 2008Inventors: Lee Mizzen, N. Chu, Huacheng Wu
-
Patent number: 7262014Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.Type: GrantFiled: September 10, 2004Date of Patent: August 28, 2007Assignee: Stressgen Biotechnologies CorporationInventors: Lee A. Mizzen, N. Randall Chu, Huacheng Bill Wu
-
Publication number: 20070160620Abstract: The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein.Type: ApplicationFiled: December 7, 2006Publication date: July 12, 2007Inventors: Lee Mizzen, Lawrence Anthony, Huacheng Wu, Marvin Siegel
-
Patent number: 7157089Abstract: The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein.Type: GrantFiled: November 25, 1997Date of Patent: January 2, 2007Assignee: Stressgen Biotechnologies CorporationInventors: Lee Mizzen, Lawrence S. D. Anthony, Huacheng Bill Wu, Marvin Siegel
-
Publication number: 20060039922Abstract: Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response to Streptococcal bacteria.Type: ApplicationFiled: August 11, 2005Publication date: February 23, 2006Inventors: Lee Mizzen, Jan Wisniewski
-
Publication number: 20050202044Abstract: The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce the immune response against the antigen. In a particular embodiment, the present invention relates to vaccines and compositions which induce a CTL response in a mammal comprising an antigen and all or a portion of a stress protein. In another embodiment, the invention relates to vaccines and compositions which induce an immune response to an influenza virus in a mammal comprising an antigen of the influenza virus and all or a portion of one or more stress proteins. The invention also relates to vaccines and compositions for inducing a CTL response to a tumor-associated antigen comprising a tumor-associated antigen and all or a portion of the stress protein.Type: ApplicationFiled: February 19, 2004Publication date: September 15, 2005Inventors: Lee Mizzen, Lawrence Anthony, Huacheng Wu, Marvin Siegel
-
Publication number: 20050176672Abstract: A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.Type: ApplicationFiled: April 6, 2005Publication date: August 11, 2005Inventors: Ronald Scheule, Nelson Yew, Lee Mizzen, Salam Kadhim
-
Patent number: 6921534Abstract: The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.Type: GrantFiled: February 5, 2002Date of Patent: July 26, 2005Assignee: Stressgen Biotechnologies CorporationInventors: Lee A. Mizzen, Marvin Siegel, Hongwei Liu
-
Publication number: 20050152917Abstract: The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.Type: ApplicationFiled: September 14, 2004Publication date: July 14, 2005Inventors: Lee Mizzen, Marvin Siegel, Hongwei Liu
-
Patent number: 6900035Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.Type: GrantFiled: November 7, 2002Date of Patent: May 31, 2005Assignee: Stressgen Biotechnologies, Inc.Inventors: Lee A. Mizzen, N. Randall Chu, Huacheng Bill Wu
-
Publication number: 20050089841Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.Type: ApplicationFiled: October 6, 2003Publication date: April 28, 2005Inventors: Marvin Siegel, N. Chu, Lee Mizzen
-
Publication number: 20050037017Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.Type: ApplicationFiled: September 10, 2004Publication date: February 17, 2005Inventors: Lee Mizzen, N. Chu, Huacheng Wu
-
Patent number: 6657055Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.Type: GrantFiled: October 9, 2002Date of Patent: December 2, 2003Assignee: Stressgen Biotechnologies CorporationInventors: Marvin Siegel, N. Randall Chu, Lee A. Mizzen
-
Publication number: 20030148456Abstract: The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein.Type: ApplicationFiled: November 7, 2002Publication date: August 7, 2003Applicant: Stressgen Biotechnologies, Inc., a British Columbia, Canada corporationInventors: Lee A. Mizzen, N. Randall Chu, Huacheng Bill Wu
-
Publication number: 20030050469Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.Type: ApplicationFiled: October 9, 2002Publication date: March 13, 2003Applicant: Stressgen Biotechnologies Corporation, a Victoria, Canada corporationInventors: Marvin Siegel, N. Randall Chu, Lee A. Mizzen
-
Patent number: 6524825Abstract: The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein.Type: GrantFiled: February 4, 2000Date of Patent: February 25, 2003Assignee: Stressgen Biotechnologies, Inc.Inventors: Lee A. Mizzen, N. Randall Chu, Huacheng Bill Wu
-
Patent number: 6495347Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.Type: GrantFiled: July 10, 2000Date of Patent: December 17, 2002Assignee: Stressgen Biotechnologies CorporationInventors: Marvin Siegel, N. Randall Chu, Lee A. Mizzen
-
Publication number: 20020155434Abstract: The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.Type: ApplicationFiled: February 5, 2002Publication date: October 24, 2002Inventors: Lee A. Mizzen, Marvin Siegel, Hongwei Liu